Two units of US drug giant Johnson & Johnson have filed a lawsuit seeking preliminary discovery from Juno Pharmaceuticals for a possible patent lawsuit over a popular chemotherapy drug used to treat blood cancer.
Neurim Pharmaceuticals can seek limited additional damages in a patent infringement case relating to its insomnia drug Circadin, after a judge granted a mid-trial bid to amend its pleadings against Generic Partners and Apotex.
A judge has enjoined Merck Sharpe and Dohme from launching its 15-valent pneumococcal conjugate vaccine after finding it would infringe claims of a Wyeth patent for its Prevnar 13 vaccine, despite MSD’s argument that barring it from launching the vaccine would be contrary to the public interest.
Pharmaceutical ingredients company Alkaloids of Australia and former export manager Christopher Joyce have been charged over a cartel following a price-fixing investigation by the ACCC linked to the active ingredient in stomach cramp drug Buscopan.
Two psychiatrists at the heart of the Chelmsford deep sleep therapy scandal have had their defamation cases against publisher HarperCollins dismissed ,with a judge finding the lawsuits were an attempt to “rewrite history” regarding harm done to patients receiving their controversial treatment.
The lead applicant in a class action against Bayer over allegedly defective Essure contraceptive devices will ask the court to discontinue its claims against two makers of the controversial medical implants.
A judge has dismissed Pfizer’s bid for preliminary discovery to pursue a possible patent infringement case against drug maker Sandoz over a generic version of its blockbuster rheumatoid arthritis biologic Enbrel.
National medical centre operator Healius has agreed to pay back wages of $15.3 million to thousands of nurses, doctors and dentists after reporting “widespread underpayments” for over eight years.
A nursing home in Melbourne’s Western suburbs may be hit with a class action over a COVID-19 outbreak at the facility that resulted in the deaths of 11 residents.
The High Court has declined to take up Mylan’s challenge to a Full Court ruling upholding the invalidity of three patents for its blockbuster cholesterol drug Lipidil.